Speaker Details

Naiem Issa, MD, PhD, FAAD

Naiem Issa, MD, PhD, FAAD

SESSIONS

F098 Chronic Spontaneous Urticaria: A Review of the Basics and New and Emerging Drugs
Mar 30, 2026 3:30 PM - 5:30 PM Mile High 4D

DISCLOSURES

AbbVie – Speaker(Fees); Almirall – Advisory Board(Fees), Speaker(Fees); Apogee Therapeutics – Consultant (1099 relationship)(Fees); Boehringer Ingelheim – Speaker(Fees); Botanix Pharmaceuticals – Speaker(Fees); Bristol Myers Squibb – Advisory Board(Fees), Speaker(Fees); Castle Biosciences – Advisory Board(Fees); Dermavant Sciences, Inc. – Advisory Board(Fees), Speaker(Fees); DermTech Inc. – Consultant (1099 relationship)(Fees), Speaker(Fees); Eli Lilly – Advisory Board(Fees), Investigator(Grants/Research Funding); Galderma – Advisory Board(Fees), Consultant (1099 relationship)(Fees), Speaker(Fees); Incyte Corporation – Speaker(Fees); Journey Medical Corporation – Consultant (1099 relationship)(Fees), Speaker(Fees); LEO Pharma, US – Advisory Board(Fees), Speaker(Fees); National Eczema Association – Consultant (1099 relationship)(Fees); Novartis – Advisory Board(Fees), Speaker(Fees); Ortho Dermatologics – Speaker(Fees); Oruka Therapeutics – Consultant (1099 relationship)(Fees); Pfizer Inc. – Advisory Board(Fees), Speaker(Fees); Sanofi/Regeneron – Speaker(Fees); Sun Pharmaceutical Industries Ltd. – Advisory Board(Fees), Speaker(Fees); Topix Pharmaceuticals, Inc. – Consultant (1099 relationship)(Fees); UCB – Advisory Board(Fees); Verrica Pharmaceuticals Inc – Speaker(Fees), Stockholder Public Company(Stock);